MX2018009389A - Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos. - Google Patents

Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.

Info

Publication number
MX2018009389A
MX2018009389A MX2018009389A MX2018009389A MX2018009389A MX 2018009389 A MX2018009389 A MX 2018009389A MX 2018009389 A MX2018009389 A MX 2018009389A MX 2018009389 A MX2018009389 A MX 2018009389A MX 2018009389 A MX2018009389 A MX 2018009389A
Authority
MX
Mexico
Prior art keywords
antibodies
protein
methods
binding polypeptides
epha2 antibodies
Prior art date
Application number
MX2018009389A
Other languages
English (en)
Inventor
Kohli Neeraj
Geddie Melissa
D Marks James
Drummond Daryl
Kirpotin Dmitri
Lugovsky Alexey
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2018009389A publication Critical patent/MX2018009389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente descripción anticuerpos (por ejemplo, scFv) que incluyen CDR y regiones de marco humanas que confieren propiedades sobre los anticuerpos. En determinadas modalidades, dichas propiedades incluyen termoestabilidad (por ejemplo, un aumento en la temperatura de fusión), unión eficaz a la Proteína A de Staphylococcus aureus o ambas. En determinados aspectos, los anticuerpos son anticuerpos de internalización que se unen específicamente al antígeno EphA2 relacionado con el tumor.
MX2018009389A 2016-03-16 2017-03-13 Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos. MX2018009389A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662309374P 2016-03-16 2016-03-16
US201662309365P 2016-03-16 2016-03-16
US201662309383P 2016-03-16 2016-03-16
PCT/US2017/022188 WO2017160775A1 (en) 2016-03-16 2017-03-13 Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018009389A true MX2018009389A (es) 2018-11-21

Family

ID=59852234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009389A MX2018009389A (es) 2016-03-16 2017-03-13 Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.

Country Status (12)

Country Link
US (1) US20170267768A1 (es)
EP (1) EP3429624A4 (es)
JP (1) JP2019515645A (es)
KR (1) KR20180127344A (es)
CN (1) CN108778328A (es)
AU (1) AU2017234275A1 (es)
BR (1) BR112018015898A2 (es)
CA (1) CA3016676A1 (es)
MX (1) MX2018009389A (es)
SG (1) SG11201807336RA (es)
TW (1) TW201738275A (es)
WO (1) WO2017160775A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011280893C1 (en) * 2010-07-22 2016-02-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
CN109467593A (zh) * 2018-11-30 2019-03-15 北京泽勤生物医药有限公司 低pH插入肽的胞外段作为抗原的应用
CN114437205A (zh) * 2020-11-05 2022-05-06 多玛医药科技(苏州)有限公司 抗冠状病毒抗体及其应用
WO2022250431A1 (ko) 2021-05-25 2022-12-01 주식회사 박셀바이오 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포
CN116970077A (zh) * 2021-07-16 2023-10-31 西南医科大学 一种抗EphA2全人源双价重组抗体scFv-Fc
KR20230022810A (ko) * 2021-08-06 2023-02-16 한국생명공학연구원 신규한 항-EphA2 키메릭 항원 수용체 및 이를 발현하는 면역세포
CN113980138B (zh) * 2021-08-11 2023-08-11 卡瑞济(北京)生命科技有限公司 EphA2嵌合抗原受体以及其用途
WO2023196869A1 (en) * 2022-04-05 2023-10-12 Atreca, Inc. Epha2 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
SI2352763T2 (sl) * 2008-10-01 2022-11-30 Amgen Research (Munich) Gmbh Bispecifična enoverižna protitelesa s specifičnostjo za tarčne antigene z visoko molekulsko maso
US20130022604A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa
AU2011280893C1 (en) * 2010-07-22 2016-02-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
US20130310281A1 (en) * 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
KR101632620B1 (ko) * 2011-07-27 2016-06-23 글락소 그룹 리미티드 Ｆｃ 도메인에 융합된 항­ｖｅｇｆ 단일 가변 도메인
EP2716298A1 (en) * 2012-10-03 2014-04-09 Institut Pasteur A nod2-dependant pathway of cytoprotection of stem cells
CA3016455A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions

Also Published As

Publication number Publication date
WO2017160775A1 (en) 2017-09-21
CN108778328A (zh) 2018-11-09
AU2017234275A1 (en) 2018-10-04
JP2019515645A (ja) 2019-06-13
EP3429624A4 (en) 2020-04-22
US20170267768A1 (en) 2017-09-21
TW201738275A (zh) 2017-11-01
KR20180127344A (ko) 2018-11-28
CA3016676A1 (en) 2017-09-21
EP3429624A1 (en) 2019-01-23
SG11201807336RA (en) 2018-09-27
BR112018015898A2 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
MX2018009389A (es) Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
NZ738008A (en) Tigit-binding agents and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12016501644B1 (en) Binding proteins and methods of use thereof
HK1244219A1 (zh) 結合cd3和腫瘤抗原的異二聚體抗體
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
EP3258967A4 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EA201791093A1 (ru) Антитела к cd47, способы и применение
WO2015109124A3 (en) Immunomodulatory agents
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
NZ745635A (en) Binding proteins and methods of use thereof
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EP3418305A4 (en) METHODS OF EXPRESSION AND PREPARATION OF BIVALENT BISPECIFIC ANTIBODY HYBRID PROTEIN
WO2017019957A3 (en) Binding proteins and methods of use thereof
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof